Article

Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study

Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU206PH, UK.
European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology (Impact Factor: 4.37). 07/2009; 19(8):542-50. DOI: 10.1016/j.euroneuro.2009.03.003
Source: PubMed

ABSTRACT

SOHO is a 3-year, prospective, observational study of schizophrenia patients who started a new antipsychotic in 10 European countries. Cohorts of patients were defined according to the antipsychotic started at baseline: olanzapine, risperidone, quetiapine, amisulpride, clozapine, oral typical and depot typical antipsychotics. Tolerability in terms of rates of extrapyramidal symptoms (EPS), tardive dyskinesia (TD), anticholinergic use, loss of libido/impotence, amenorrhoea/galactorrhoea/gynaecomastia, and weight change was assessed in 4939 patients who started monotherapy. Logistic regression models related medication initiated at study entry to adverse events over follow-up, adjusting by baseline differences among treatment cohorts. Patients taking typical antipsychotics or risperidone were more likely to experience EPS and TD during follow-up than patients taking olanzapine. Patients taking olanzapine were less likely to have loss of libido/impotence during follow-up than patients in the risperidone, amisulpride, clozapine, oral typical and depot typical cohorts. Weight gain occurred in all groups, but was greater with olanzapine. In conclusion, antipsychotics have different tolerability profiles in terms of the adverse events we monitored. Results should be interpreted conservatively due to the observational study design.

Download full-text

Full-text

Available from: Elena Perrin, Mar 22, 2014
  • Source
    • "Antipsychotics are effective drugs for controlling psychotic symptoms in some mental disorders, such as schizophrenia. However, both typical (e.g., haloperidol) and atypical (e.g., clozapine and olanzapine) antipsychotics exert troublesome side effects that decrease adherence to treatment and affect the quality of life of patients (Novick et al., 2009; Serretti and Chiesa, 2011; Tandon et al., 2008). Furthermore, schizophrenia patients refractory to current antipsychotics are unlikely to respond to new antipsychotics that target the dopamine D 2 receptor (Stone et al., 2010). "

    Full-text · Article · Sep 2011 · European Neuropsychopharmacology
  • Source
    • "Antipsychotics are effective drugs for controlling psychotic symptoms in some mental disorders, such as schizophrenia. However, both typical (e.g., haloperidol) and atypical (e.g., clozapine and olanzapine) antipsychotics exert troublesome side effects that decrease adherence to treatment and affect the quality of life of patients (Novick et al., 2009; Serretti and Chiesa, 2011; Tandon et al., 2008). Furthermore, schizophrenia patients refractory to current antipsychotics are unlikely to respond to new antipsychotics that target the dopamine D 2 receptor (Stone et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myricitrin is a nitric oxide (NO) and protein kinase C (PKC) inhibitor that has central nervous system activity, including anxiolytic-like action. Nitric oxide inhibitors blocked the behavioral effects of apomorphine, suggesting an antipsychotic-like effect. Furthermore, PKC inhibition reduced psychotic symptoms in acute mania patients and blocked amphetamine-induced hyperlocomotion, suggesting a potential antipsychotic-like effect. The present study evaluated the effects of myricitrin in animal models that assess antipsychotic-like effects (apomorphine-induced stereotypy and climbing and the paw test) and extrapyramidal side effects (catalepsy test and paw test). Olanzapine was used as a positive control. 7-Nitroindazole (7-NI), a NOS inhibitor, and l-arginine, a NO precursor, were used to evaluate nitrergic modulation, and tamoxifen was used to test the effect of PKC inhibition. In mice, myricitrin dose-dependently and olanzapine blocked the stereotypy and climbing induced by apomorphine at doses that did not induce catalepsy. 7-Nitroindazole also blocked apomorphine-induced stereotypy and climbing, which were reversed by l-arginine pretreatment. l-arginine only attenuated the effects of myricitrin on apomorphine's effects. Tamoxifen also blocked apomorphine-induced stereotypy and climbing. In the paw test in rats, myricitrin and olanzapine increased hindlimb retraction time at doses that did not affect forelimb reaction time, whereas haloperidol affected both parameters at the same dose. Myricitrin did not induce catalepsy in the bar test. Tamoxifen did not affect hindlimb retraction time or forelimb retraction time, whereas 7-NI significantly increased hindlimb reaction time. Thus, myricitrin exhibited an antipsychotic-like profile at doses that did not induce catalepsy, and this effect may be related to nitrergic action.
    Full-text · Article · Jun 2011 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • Source
    • "Note that none of the participants were referred into the study because of the sexual side effects of antipsychotic drug treatment. Sexual side effects can lessen with time following a treatment switch [44]. This reduction over time could, in part, explain the improvement in sexual function seen in the SGA group but fails to account for the deterioration seen in the FGA group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The impact of antipsychotic drug treatment on sexual function was investigated during a randomised trial comparing first generation antipsychotics (FGAs) to (nonclozapine) second generation antipsychotics (SGAs). Sexual function and quality of life were (rater-blind) assessed in 42 patients with DSM-IV schizophrenia (aged 18-65) using the self-report version of the Derogatis Interview for Sexual Function (DISF-SR) and the Heinrichs Quality of Life Scale (QLS), prior to, and 12 weeks following, a change in medication from an FGA drug to either an FGA or SGA drug. SGAs significantly improved sexual function compared to FGAs. Change in sexual function was associated with change in quality of life. Where impaired sexual functioning is a distressing adverse effect of treatment with an FGA agent, consideration should be given to switching to an SGA.
    Full-text · Article · Jan 2011
Show more